Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ILMN
Illumina, Inc. (ILMN) Return on equity
Illumina, Inc.'s return on equity over the twelve months to 30 June 2026 was 32.4%, down 1.0 percentage points from fiscal 2025 (33.4%). Over the past ten years it has ranged from −50.8% (fiscal 2022) to 33.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 33.4% | 63.49 |
| FY2024 | −30.1% | (11.32) |
| FY2023 | −18.8% | 31.99 |
| FY2022 | −50.8% | (60.67) |
| FY2021 | 9.87% | (4.23) |
| FY2020 | 14.1% | (9.59) |
| FY2019 | 23.7% | (1.36) |
| FY2018 | 25.1% | (3.88) |
| FY2017 | 28.9% | 6.45 |
| FY2016 | 22.5% | (5.42) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. compare | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| LH Labcorp Holdings Inc. compare | 11.7% |
| WAT Waters Corporation compare | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ILMN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement